Pague Menos Q1 2026 slides: revenue beats amid EPS miss

Pague Menos posted Q1 2026 gross revenue of BRL 4.14 billion, up 14.4% year over year and above estimates, while adjusted EBITDA rose 36.1% to BRL 204.7 million and gross margin expanded to 29.5%. The main negative was EPS of BRL 0.0516, which missed the BRL 0.08 consensus by 35.5% because of elevated financial expenses, even as leverage improved to 1.9x net debt/EBITDA and Fitch revised its outlook to positive. Management guided to full-year 2026 EPS of BRL 0.12 and revenue of BRL 3.64 billion, with shares down 0.37% on the report.

Analysis

The important read-through is not the headline EPS miss; it is that Pague Menos is transitioning from a pure turnaround into a quality compounding story where operating leverage is now visible enough to support multiple expansion, but only if the market believes financing costs are peaking. The deleveraging step-change and rating outlook improvement reduce the equity risk premium, which matters more than the quarterly earnings print because Brazilian food/pharmacy retail equity valuations are usually driven by balance-sheet confidence before headline earnings. That creates a second-order beneficiary set: suppliers and landlords should see improving counterparty risk, while smaller regional pharmacy chains with weaker credit access may struggle to match commercial terms and inventory availability.

The market is likely underappreciating how much of the growth is now coming from higher-frequency chronic-care behavior rather than pure traffic, which makes revenue more defensive and improves forecastability over the next 4-8 quarters. The omnichannel mix shift also raises the barrier to entry because it lowers customer acquisition cost and increases switching friction, especially in the North/Northeast where Pague Menos already has density advantages. If management sustains this mix, the company can widen the gap versus national peers even without aggressive store expansion, making the current share-price weakness look more like de-risking than deterioration.

The key risk is that financial expense relief may take longer than the market wants, and if rate expectations or funding spreads re-widen, the earnings-to-cash-flow conversion will remain choppy despite strong EBITDA. Another risk is that the new distribution center temporarily lengthens inventory cycles; that is manageable if demand stays strong, but it could pressure working capital and free cash flow just as the company is signaling faster openings. In the near term, the stock can stay range-bound for weeks if investors fixate on EPS, but over a 3-6 month horizon a couple of clean quarters of debt reduction could re-rate the name materially.

Key Decisions for Investors

• Long PGMN3 on weakness for a 3-6 month horizon; the setup is a balance-sheet re-rating trade more than a one-quarter earnings trade. Use a staggered entry below recent post-earnings levels; downside is limited by de-risked leverage, upside is multiple expansion if spreads keep tightening.
• Pair trade: long PGMN3 / short a more levered Brazilian discretionary or pharmacy peer with weaker cash conversion. The spread should widen if funding costs remain elevated, because PGMN3 has clearer deleveraging optionality and better supplier negotiating power.
• Buy medium-dated call spreads on PGMN3 rather than outright stock if liquidity allows; the catalyst is 2Q-3Q confirmation that EPS is inflecting as financial expenses normalize. This offers defined downside while preserving upside from a re-rating.
• If you own Brazilian consumer baskets, overweight PGMN3 versus broad retail exposure because chronic-care demand and omnichannel penetration make revenue more resilient than discretionary retail. The relative trade should work even in a slower macro environment.
• Set a risk trigger to reduce exposure if net debt/EBITDA stalls above ~2x for two consecutive quarters or if inventory days continue to rise after the new DC ramp. Those are the signals that operating momentum is being consumed by working-capital drag.